Abstract
Parkinson’s disease (PD) was first formally described by James Parkinson in 1817, but the shaking of limbs was described in the literature of several ancient civilizations, such as ancient Chinese civilization and ancient Indian civilization. Historically, botanical drugs were used as the main source for the treatment of such kind of disorders. In Western countries, plant extracts also occupied an important place in the earlier medications of PD. With the adventure of synthetic drugs, the role of plant-derived drugs in management of PD has been diminished. Nowadays, there is still no cure for PD, dopaminergic (DA) medication is the treatment of choice, which is just designed to ameliorate symptoms of PD, and long-term use of DA medication will result in reduced efficacy and severe adverse reactions. It is necessary to explore new methods for the treatment of PD. Chinese medicine (CM) developed a holistic and unique theoretical system, and botanical drugs are widely used in practice for more than two millennia. Modern pharmacological studies have proved that Chinese herbs have potential therapeutic effects on PD, such as enhancing neurotrophic activity, clearing protein aggregates, regulating neuroinflammation, etc. All the advances provide us with hope for developing CM as a mainstream medication for treating PD.
Similar content being viewed by others
References
Raudino F. The Parkinson disease before James Parkinson. Neurol Sci 2012;33:945–948.
Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland for Sherwood, Neely, and Jones;1817.
Donaldson IML. James Parkinson's essay on the shaking palsy. J R Coll Physicians Edinb 2015;45:84–86
Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011;1:a008862.
Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 2015;30:4–18.
Wei W, Chen HY, Fan W, et al. Chinese medicine for idiopathic Parkinson's disease: a meta analysis of randomized controlled trials. Chin J Integr Med 2017;23:55–61.
Li Q, Zhao D, Bezard E. Traditional Chinese medicine for Parkinson's disease: a review of Chinese literature. Behav Pharmacol 2006;17:403–410.
Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18(S1):S207–S209.
Tarakad A, Jankovic J. Diagnosis and management of Parkinson's disease. Semin Neurol 2017;37:118–126.
Rajput AH. Factors predictive of the development of levodopainduced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2014;29:429.
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72:S1–136.
Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis 2018;4:21.
Li G, Ma J, Cui S, et al. Parkinson's disease in China: a forty-year growing track of bedside work. Transl Neurodegener 2019;8:22.
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–386.
Kim HU, Ryu JY, Lee JO, et al. A systems approach to traditional oriental medicine. Nat Biotechnol 2015;33:264–268.
Schmidt BM, Ribnicky DM, Lipsky PE, et al. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol 2007;3:360–366.
Cunningham RW, Harned BK, Clark MC, et al. The pharmacology of 3-(N-piperidyl)-1-phenyl-1-cyclohexyl-1-propanol hydrochloric acid (artane) and related compounds; new antispasmodic agents. J Pharmacol Exp Ther 1949;96:151–165.
Lees AJ. Drugs for Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:607–610.
Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011;1:a008862.
Walusinski O. Jean-Martin Charcot and Parkinson's disease: teaching and teaching materials. Rev Neurol (Paris) 2018;174:491–505.
Schwab RS, Tillmann WR. Artane in the treatment of Parkinson's disease; a report of its effectiveness alone and in combination with benadryl and parpanit. N Engl J Med 1949;241:483–485.
Porteous HB, Ross DN. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy. Br Med J 1956;2:138–140.
Ernst AM. Relation between action of dopamine and apomorphine and the O-methylated derivates upon the CNS. Psychopharmacol (Berl) 1965;7:391–399.
Lees A, Turner K. Apomorphine for Parkinson's disease. Pract Neurol 2002;2:280–286.
Parkes JD, Marsden CD, Donaldson I, et al. Bromocriptine treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1976;39:184–193.
Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826–829.
Tan LC, Ng KK, Au WL, et al. Bromocriptine use and the risk of valvular heart disease. Mov Disord 2009;24:344–349.
Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations. CNS Drugs 2019;33:905–918.
Srivastav S, Fatima M, Mondal AC. Important medicinal herbs in Parkinson's disease pharmacotherapy. Biomed Pharmacother 2017;92:856–863.
Hornykiewicz O. A brief history of levodopa. J Neurol 2010;257(Suppl 2):S249–S252.
Damodaran M, Ramaswamy R. Isolation of L-DOPA from the seeds of Mucuna pruriens. Biochemistry 1937;31:2149–2151.
Manyam BV. Paralysis agitans and levodopa in “Ayurveda”: ancient Indian medical treatise. Mov Disord 1990;5:47–48.
Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75:1672–1677.
Cilia R, Laguna J, Cassani E, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology 2017;89:432–438.
Schmidt B, Ribnicky DM, Poulev A, et al. A natural history of botanical therapeutics. Metabolism 2008;57(7 Suppl 1):S3–S9.
Liang SC, Ge GB, Xia YL, et al. Inhibition of human catechol-Omethyltransferase-mediated dopamine O-methylation by daphnetin and its phase II metabolites. Xenobiotica 2017;47:498–504.
Engelbrecht I, Petzer JP, Petzer A. Evaluation of selected natural compounds as dual inhibitors of catechol-O-methyltransferase and monoamine oxidase. Cent Nerv Syst Agents Med Chem 2019;19:133–145.
Parasuraman S, Thing GS, Dhanaraj SA. Polyherbal formulation: concept of Ayurveda. Pharmacogn Rev 2014;8:73–80.
Song JX, Sze SCW, Ng TB, et al. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 2012;139:698–711.
Nagashayana N, Sankarankutty P, Nampoothiri MR, et al. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci 2000;176:124–127.
Ahmad M, Saleem S, Ahmad AS, et al. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol 2005;24:137–147.
Sankar SR, Manivasagam T, Krishnamurti A, et al. The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables. Cell Mol Biol Lett 2007;12:473–481.
Khurana N, Gajbhiye A. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease. Neurotoxicol 2013;39:57–64.
Han L, Xie YH, Wu R, et al. Traditional Chinese medicine for modern treatment of Parkinson's disease. Chin J Integr Med 2017;23:635–640.
Zheng GQ. Therapeutic history of Parkinson's disease in Chinese medical treatises. J Altern Complement Med 2009;15:1223–1230.
Ren ZL, Zuo PP. Neural regeneration: role of traditional Chinese medicine in neurological diseases treatment. J Pharmacol Sci 2012;120:139–145.
Tian YY, Tang CJ, Wu J, et al. Parkinson's disease in China. Neurol Sci 2011;32:23–30.
Zhang ZX, Dong ZH, Román GC. Early descriptions of Parkinson disease in ancient China. Arch Neurol 2006;63:782–784.
Raudino F. The Parkinson disease before James Parkinson. Neurol Sci 2012;33:945–948.
Chen H, Zhang Z, He J, et al. Traditional Chinese medicine symptom pattern analysis for Parkinson's disease. J Tradit Chin Med 2017;37:688–694.
Zheng GQ. Therapeutic history of Parkinson's disease in Chinese medical treatises. J Altern Complement Med 2009;15:1223–1230.
Zhang QJ, Zhang YY, Huang WY. Traditional Chinese medicine in treatment of Parkinson's disease. J Integr Med (Chin) 2004;2:75–77.
Liu H, Xie YM, Yi DH, et al. Analysis on clinical characteristics of Parkinsonism inpatients based on hospital information system. J Tradit Chin Med (Chin) 2014;55:1966–1968.
Sheng HM, He JC, Wang WW, et al. The literature research of syndromes of TCM about Parkinson's disease. Lishizhen Med Mater Med Res (Chin) 2011;22:967–969.
Li J, Jin M, Wang L, et al. MDS clinical diagnostic criteria for Parkinson's disease in China. J Neurol 2017;264:476–481.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–1601.
Zhang RC, Huang SJ, Wang YY. Deficient qi retention and pathogenesis of Parkinson's disease. J Beijing Univ Tradit Chin Med (Chin) 2013;36:805–807.
Pan XW, Zhang XG, Chen XC, et al. A survey of application of complementary and alternative medicine in Chinese patients with Parkinson's disease: a pilot study. Chin J Integr Med 2020;26:168–173.
Zuo P. Clinical study on Tianma Gouteng Granules combined with selegiline in treatment of Parkinson's disease. Drugs Clinic (Chin) 2018;33:1902–1906.
Chua KK, Chau SC, Li M. Experimental and clinical research literature review of Tianma Gouteng Yin on the treatment of Parkinson's disease. Hong Kong J Tradit Chin Med (Chin) 2012;7:66–70.
Liu LF, Song JX, Lu JH, et al. Tianma Gouteng Yin, a traditional Chinese medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson's disease. Sci Rep 2015;5:16862.
Kum WF, Durairajan SS, Bian ZX, et al. Treatment of idiopathic Parkinson's disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study. Evid Based Complement Alternat Med 2011;2011:724353.
Li WW, Cai DF, Chen XQ. Effects of Yanggan Xifeng Recipe on the neurobehavior of Parkinson's disease rats models. Chin J Integr Tradit West Med (Chin) 2000;20:920–922.
Bao XX, Ma HH, Ding H, et al. Preliminary optimization of a Chinese herbal medicine formula based on the neuroprotective effects in a rat model of rotenone-induced Parkinson's disease. J Integr Med 2018;16:290–296.
Zhu M, Lu C, Li W. Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem 2013;124:571–580.
Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Rev 1998;27:1–39.
Sautter J, Meyer M, Spenger C, et al. Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons. Neuroreport 1998;9:1093–1096.
Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 2000;21:93–98.
Hosseini R, Moosavi F, Rajaian H, et al. Discovery of neurotrophic agents based on hydroxycinnamic acid scaffold. Chem Biol Drug Des 2016;88:926–937.
Zhu M, Lu C, Li W. Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem 2013;124:571–580.
Xu G, Xiong Z, Yong Y, et al. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum. Neuroscience 2010;167:174–184.
Ryu S, Jeon H, Koo S, et al. Korean red ginseng enhances neurogenesis in the subventricular zone of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Front Aging Neurosci 2018;10:355.
Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3–12.
Hou X, Watzlawik JO, Fiesel FC, et al. Autophagy in Parkinson's disease. J Mol Biol 2020. doi: 10.1016/j.jmb.2020.01.037. [Epub ahead of print]
Chen LL, Song JX, Lu JH, et al. Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway. J Neuroimmune Pharmacol 2014;9:380–387.
Hu G, Gong X, Wang L, et al. Triptolide promotes the clearance of α-synuclein by enhancing autophagy in neuronal cells. Mol Neurobiol 2017;54:2361–2372.
Law BYK, Wu AG, Wang MJ, et al. Chinese medicine: a hope for neurodegenerative diseases? J Alzheimers Dis 2017;60(s1):S151–S160.
Sanchez-Guajardo V, Barnum CJ, Tansey MG, et al. Neuroimmunological processes in Parkinson's disease and their relation to a-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013;5:113–139.
Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 2006;38:333–347.
Zhou Y, Lu M, Du RH, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Mol Neurodegener 2016;11:28.
Gao JP, Sun S, Li WW, et al. Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease. Neurosci Bull 2008;24:133–142.
Faust K, Gehrke S, Yang Y, et al. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci 2009;10:109.
Zhang X, Yang Y, Du L, et al. Baicalein exerts anti-neuroinflammatory effects to protect against rotenone-induced brain injury in rats. Int Immunopharmacol 2017;50:38–47.
Hung KC, Huang HJ, Wang YT, et al. Baicalein attenuates a-synuclein aggregation, inflammasome activation and autophagy in the MPP+-treated nigrostriatal dopaminergic system in vivo. J Ethnopharmacol 2016;194:522–529.
Liu SM, Li XZ, Zhang SN, et al. Acanthopanax senticosus protects structure and function of mesencephalic mitochondria in a mouse model of Parkinson's disease. Chin J Integr Med 2018;24:835–843.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the National Natural Science Foundation of China (No. 81973642) and the Foundation of Shanghai Public Health Clinical Center (No. RCJJ2019-02)
Rights and permissions
About this article
Cite this article
Li, Ww. Botanical Therapeutics for Parkinson’s Disease. Chin. J. Integr. Med. 26, 405–411 (2020). https://doi.org/10.1007/s11655-020-3096-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-020-3096-5